In the last trading session, 1.88 million shares of the Immunome Inc (NASDAQ:IMNM) were traded, and its beta was 1.79. Most recently the company’s share price was $9.44, and it changed around -$0.46 or -4.75% from the last close, which brings the market valuation of the company to $523.62M. IMNM currently trades at a discount to its 52-week high of $30.96, offering almost -227.97% off that amount. The share price’s 52-week low was $6.93, which indicates that the current value has risen by an impressive 26.59% since then. We note from Immunome Inc’s average daily trading volume that its 10-day average is 0.89 million shares, with the 3-month average coming to 658.24K.

Immunome Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended IMNM as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Immunome Inc is expected to report earnings per share of -0.66 for the current quarter.

Immunome Inc (NASDAQ:IMNM) trade information

Instantly IMNM has showed a red trend with a performance of -4.75% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 13.09 on recent trading dayincreased the stock’s daily price by 27.88%. The company’s shares are currently down -11.82% year-to-date, but still down -28.85% over the last five days. On the other hand, Immunome Inc (NASDAQ:IMNM) is -23.17% down in the 30-day period. We can see from the shorts that 10.47 million shares have been sold at a short interest cover period of 18.28 day(s).

The consensus price target as assigned by Wall Street analysts is $33, which translates to bulls needing to increase their stock price by 71.39% from its current value. Analyst projections state that IMNM is forecast to be at a low of $23 and a high of $35.

Immunome Inc (IMNM) estimates and forecasts

Immunome Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -31.63 percent over the past six months and at a -232.06% annual growth rate that is well below the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -341.04% in revenue this quarter, and will report an increase of 76.89% in the next quarter. The year-over-year growth rate is expected to be -32.90%, down from the previous year.

Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 3.16M in revenue for the current quarter. The company’s sales for the same quarters a year ago were 3.83M and 1.03M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -17.51%. Forecasts for the next quarter put sales growth at -100.00%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -48.48%.

IMNM Dividends

Immunome Inc’s next quarterly earnings report is expected to be released in December.

Immunome Inc (NASDAQ:IMNM)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 16.77% of Immunome Inc shares, and 83.45% of them are in the hands of institutional investors. The stock currently has a share float of 100.27%. Immunome Inc stock is held by 171.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 36.4624% of the shares, which is about 3.76 million shares worth $45.48 million.

STATE STREET CORP, with 22.934% or 2.36 million shares worth $28.61 million as of 2024-06-30, holds the second largest percentage of outstanding shares.